View Future GrowthGL Pharm Tech 과거 순이익 실적과거 기준 점검 0/6GL Pharm Tech은 연평균 26.9%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 9.7%의 비율로 증가했습니다. 매출은 연평균 23.9%의 비율로 증가했습니다.핵심 정보26.87%순이익 성장률34.96%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률11.32%매출 성장률23.87%자기자본이익률-0.66%순이익률-0.36%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • Nov 12Third quarter 2025 earnings released: EPS: ₩2.00 (vs ₩2.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩2.00 (up from ₩2.00 loss in 3Q 2024). Revenue: ₩9.53b (up 104% from 3Q 2024). Net income: ₩132.8m (up ₩250.4m from 3Q 2024). Profit margin: 1.4% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • May 16First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: ₩7.84b (up 34% from 1Q 2024). Net income: ₩24.1m (up ₩1.66b from 1Q 2024). Profit margin: 0.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.Reported Earnings • Mar 22Full year 2024 earnings released: ₩31.00 loss per share (vs ₩60.00 loss in FY 2023)Full year 2024 results: ₩31.00 loss per share (improved from ₩60.00 loss in FY 2023). Revenue: ₩26.0b (flat on FY 2023). Net loss: ₩2.34b (loss narrowed 38% from FY 2023). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.Reported Earnings • Mar 21Full year 2023 earnings released: ₩60.00 loss per share (vs ₩13.00 loss in FY 2022)Full year 2023 results: ₩60.00 loss per share (further deteriorated from ₩13.00 loss in FY 2022). Revenue: ₩26.0b (up 56% from FY 2022). Net loss: ₩3.75b (loss widened 374% from FY 2022). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 15Third quarter 2023 earnings released: ₩15.00 loss per share (vs ₩5.00 loss in 3Q 2022)Third quarter 2023 results: ₩15.00 loss per share (further deteriorated from ₩5.00 loss in 3Q 2022). Revenue: ₩7.69b (up 64% from 3Q 2022). Net loss: ₩963.6m (loss widened 280% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.Reported Earnings • May 14First quarter 2023 earnings released: ₩10.00 loss per share (vs ₩42.00 loss in 1Q 2022)First quarter 2023 results: ₩10.00 loss per share (improved from ₩42.00 loss in 1Q 2022). Revenue: ₩5.11b (up 103% from 1Q 2022). Net loss: ₩598.2m (loss narrowed 73% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updates공시 • Mar 13GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2026GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 257, saemaeul-ro, bundang-gu, gyeonggi-do, seongnam South Korea분석 기사 • Dec 01GL Pharm Tech (KOSDAQ:204840) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Reported Earnings • Nov 12Third quarter 2025 earnings released: EPS: ₩2.00 (vs ₩2.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩2.00 (up from ₩2.00 loss in 3Q 2024). Revenue: ₩9.53b (up 104% from 3Q 2024). Net income: ₩132.8m (up ₩250.4m from 3Q 2024). Profit margin: 1.4% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.분석 기사 • Sep 23GL Pharm Tech Corp.'s (KOSDAQ:204840) P/S Still Appears To Be ReasonableWhen you see that almost half of the companies in the Pharmaceuticals industry in Korea have price-to-sales ratios (or...New Risk • Aug 27New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.1x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risk Market cap is less than US$100m (₩90.2b market cap, or US$64.7m).Reported Earnings • May 16First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: ₩7.84b (up 34% from 1Q 2024). Net income: ₩24.1m (up ₩1.66b from 1Q 2024). Profit margin: 0.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.분석 기사 • Apr 23Revenues Tell The Story For GL Pharm Tech Corp. (KOSDAQ:204840) As Its Stock Soars 45%The GL Pharm Tech Corp. ( KOSDAQ:204840 ) share price has done very well over the last month, posting an excellent gain...New Risk • Apr 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩5.0b free cash flow). Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₩109.2b market cap, or US$76.8m).Reported Earnings • Mar 22Full year 2024 earnings released: ₩31.00 loss per share (vs ₩60.00 loss in FY 2023)Full year 2024 results: ₩31.00 loss per share (improved from ₩60.00 loss in FY 2023). Revenue: ₩26.0b (flat on FY 2023). Net loss: ₩2.34b (loss narrowed 38% from FY 2023). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.공시 • Mar 13GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2025GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 257, saemaeul-ro, bundang-gu, gyeonggi-do, seongnam South KoreaNew Risk • Aug 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩4.8b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩4.8b free cash flow). Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (₩80.8b market cap, or US$60.4m).분석 기사 • Jul 23Is GL Pharm Tech (KOSDAQ:204840) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Apr 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩101.2b market cap, or US$73.6m).New Risk • Mar 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩104.5b market cap, or US$77.7m).Reported Earnings • Mar 21Full year 2023 earnings released: ₩60.00 loss per share (vs ₩13.00 loss in FY 2022)Full year 2023 results: ₩60.00 loss per share (further deteriorated from ₩13.00 loss in FY 2022). Revenue: ₩26.0b (up 56% from FY 2022). Net loss: ₩3.75b (loss widened 374% from FY 2022). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.공시 • Mar 07W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity FundW Science Co., Ltd. agreed to acquire a 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund for KRW 15.77 billion on September 14, 2023. W Science Co., Ltd. entered into an agreement to acquire 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund, KAIS Inc and Hoon-sik Wang for KRW 15.77 billion on February 28, 2024. The offer per share is KRW 1700 per share. The scheduled transaction closing date is April 29, 2024. W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund on March 6, 2024.공시 • Mar 06GL Pharm Tech Corp. announced that it has received KRW 9.199999458 billion in funding from W Science Co., Ltd.On March 6, 2024, GL Pharm Tech Corp. closed the transaction.분석 기사 • Mar 01Market Participants Recognise GL Pharm Tech Corp.'s (KOSDAQ:204840) Revenues Pushing Shares 25% HigherGL Pharm Tech Corp. ( KOSDAQ:204840 ) shares have had a really impressive month, gaining 25% after a shaky period...Reported Earnings • Nov 15Third quarter 2023 earnings released: ₩15.00 loss per share (vs ₩5.00 loss in 3Q 2022)Third quarter 2023 results: ₩15.00 loss per share (further deteriorated from ₩5.00 loss in 3Q 2022). Revenue: ₩7.69b (up 64% from 3Q 2022). Net loss: ₩963.6m (loss widened 280% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.New Risk • Nov 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩3.1b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩3.1b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (₩78.1b market cap, or US$59.9m).New Risk • Jul 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩67.7b market cap, or US$52.6m).Reported Earnings • May 14First quarter 2023 earnings released: ₩10.00 loss per share (vs ₩42.00 loss in 1Q 2022)First quarter 2023 results: ₩10.00 loss per share (improved from ₩42.00 loss in 1Q 2022). Revenue: ₩5.11b (up 103% from 1Q 2022). Net loss: ₩598.2m (loss narrowed 73% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 08Third quarter 2022 earnings released: ₩5.00 loss per share (vs ₩5.00 loss in 3Q 2021)Third quarter 2022 results: ₩5.00 loss per share (in line with 3Q 2021). Revenue: ₩4.70b (up 88% from 3Q 2021). Net loss: ₩306.2m (loss narrowed 78% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.분석 기사 • Mar 30Would GL Pharm Tech (KOSDAQ:204840) Be Better Off With Less Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Dec 15The GL Pharm Tech (KOSDAQ:204840) Share Price Is Up 50% And Shareholders Are Holding OnPassive investing in index funds can generate returns that roughly match the overall market. But one can do better than...Is New 90 Day High Low • Dec 02New 90-day high: ₩1,190The company is up 17% from its price of ₩1,015 on 03 September 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.공시 • Nov 25GL Pharm Tech Corp. announced that it expects to receive KRW 4.5 billion in funding from Ideal Priavate Equity 1 Co., Ltd.GL Pharm Tech Corp. (KOSDAQ:A204840) announced a private placement of series 6 non-guaranteed private equity convertible bonds with registered interest for gross proceeds of KRW 4,500,000,000 on November 23, 2020. The transaction will include participation from Ideal Priavate Equity 1 Co., Ltd. The bonds will have interest rate of 4% and surface to interest rate 2% and will mature on November 29, 2025. The bonds to be issued are 100% convertible into 4,950,495 shares at a price of KRW 909 for 10.49% equity during the period November 30, 2021 to November 29, 2025. The subscription date is November 23, 2020 and payment date is November 30, 2020. The security to be issued in the transaction will be subject to hold period of one year. The transaction has been approved by the board of directors of the company.Is New 90 Day High Low • Oct 30New 90-day low: ₩875The company is down 14% from its price of ₩1,020 on 31 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.공시 • Sep 30GL Pharm Tech Corp. announced that it has received KRW 1.000000232 billion in funding from Kyperion Co., Ltd.On September 29, 2020, GL Pharm Tech Corp. (KOSDAQ:A204840) closed the transaction.Is New 90 Day High Low • Sep 24New 90-day low: ₩896The company is down 10.0% from its price of ₩992 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 23% over the same period.공시 • Sep 22GL Pharm Tech Corp. announced that it expects to receive KRW 1.000000232 billion in funding from Kyperion Co., Ltd.GL Pharm Tech Corp. (KOSDAQ:A204840) announced a private placement of 1,152,074 common of par value KRW 100 per share, at an issue price of KRW 868 per share for gross proceeds of KRW 1,000,000,232 on September 21, 2020. The transaction will include participation from Kyperion Co., Ltd for all the shares in the transaction. The company will raise the funding through third party allocation method. The total number of shares issued before the transaction is 46,058,145 shares. All securities to be issued in the transaction will be subject to a lock-up period of one year. The transaction was approved by the bard of directors of the company, and is expected to close on September 29, 2020. The securities are issued at 10% per discount.매출 및 비용 세부 내역GL Pharm Tech가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A204840 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Mar 2636,862-13212,3491,56631 Dec 2535,2681211,6071,91630 Sep 2534,29930711,2232,58230 Jun 2529,4455710,5571,60931 Mar 2528,053-6819,6391,75431 Dec 2426,048-2,3379,1572,32530 Sep 2424,900-3,4189,0722,04830 Jun 2427,909-4,2648,6092,86231 Mar 2426,761-4,7838,9723,14631 Dec 2326,033-3,7499,0122,37730 Sep 2325,081-2,3898,0412,43730 Jun 2322,095-1,6797,3602,30631 Mar 2319,3257975,9871,88331 Dec 2216,729-7905,6841,96830 Sep 2214,466-1,6025,0032,39630 Jun 2212,271-2,7574,7282,79631 Mar 2211,942-4,5024,4542,73231 Dec 2112,426-3,7273,1902,97430 Sep 2111,652-4,0823,3402,38330 Jun 2111,725-3,3713,1322,18931 Mar 2112,182-3,5993,0702,68431 Dec 2011,988-3,3563,1042,51830 Sep 209,630-3,6482,4292,66630 Jun 209,772-4,1802,5002,48731 Mar 2010,029-6,9672,4722,29631 Dec 1910,608-5,5152,4882,22130 Sep 1912,226-5,5052,7752,01430 Jun 1910,911-5,8443,1701,53831 Mar 199,668-3,3692,9381,81731 Dec 187,998-5,3503,2951,68030 Sep 186,487-4,6192,8581,72030 Jun 185,446-4,1052,1542,13831 Mar 183,826-4,3102,1181,55031 Dec 172,414-4,2371,4661,459양질의 수익: A204840 은(는) 현재 수익성이 없습니다.이익 마진 증가: A204840는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A204840는 수익성이 없지만 지난 5년 동안 연평균 26.9%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 A204840의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: A204840은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(6.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: A204840는 현재 수익성이 없으므로 자본 수익률이 음수(-0.66%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 09:59종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스GL Pharm Tech Corp.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Nov 12Third quarter 2025 earnings released: EPS: ₩2.00 (vs ₩2.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩2.00 (up from ₩2.00 loss in 3Q 2024). Revenue: ₩9.53b (up 104% from 3Q 2024). Net income: ₩132.8m (up ₩250.4m from 3Q 2024). Profit margin: 1.4% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 16First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: ₩7.84b (up 34% from 1Q 2024). Net income: ₩24.1m (up ₩1.66b from 1Q 2024). Profit margin: 0.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
Reported Earnings • Mar 22Full year 2024 earnings released: ₩31.00 loss per share (vs ₩60.00 loss in FY 2023)Full year 2024 results: ₩31.00 loss per share (improved from ₩60.00 loss in FY 2023). Revenue: ₩26.0b (flat on FY 2023). Net loss: ₩2.34b (loss narrowed 38% from FY 2023). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.
Reported Earnings • Mar 21Full year 2023 earnings released: ₩60.00 loss per share (vs ₩13.00 loss in FY 2022)Full year 2023 results: ₩60.00 loss per share (further deteriorated from ₩13.00 loss in FY 2022). Revenue: ₩26.0b (up 56% from FY 2022). Net loss: ₩3.75b (loss widened 374% from FY 2022). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 15Third quarter 2023 earnings released: ₩15.00 loss per share (vs ₩5.00 loss in 3Q 2022)Third quarter 2023 results: ₩15.00 loss per share (further deteriorated from ₩5.00 loss in 3Q 2022). Revenue: ₩7.69b (up 64% from 3Q 2022). Net loss: ₩963.6m (loss widened 280% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
Reported Earnings • May 14First quarter 2023 earnings released: ₩10.00 loss per share (vs ₩42.00 loss in 1Q 2022)First quarter 2023 results: ₩10.00 loss per share (improved from ₩42.00 loss in 1Q 2022). Revenue: ₩5.11b (up 103% from 1Q 2022). Net loss: ₩598.2m (loss narrowed 73% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
공시 • Mar 13GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2026GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 257, saemaeul-ro, bundang-gu, gyeonggi-do, seongnam South Korea
분석 기사 • Dec 01GL Pharm Tech (KOSDAQ:204840) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Reported Earnings • Nov 12Third quarter 2025 earnings released: EPS: ₩2.00 (vs ₩2.00 loss in 3Q 2024)Third quarter 2025 results: EPS: ₩2.00 (up from ₩2.00 loss in 3Q 2024). Revenue: ₩9.53b (up 104% from 3Q 2024). Net income: ₩132.8m (up ₩250.4m from 3Q 2024). Profit margin: 1.4% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.
분석 기사 • Sep 23GL Pharm Tech Corp.'s (KOSDAQ:204840) P/S Still Appears To Be ReasonableWhen you see that almost half of the companies in the Pharmaceuticals industry in Korea have price-to-sales ratios (or...
New Risk • Aug 27New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.1x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risk Market cap is less than US$100m (₩90.2b market cap, or US$64.7m).
Reported Earnings • May 16First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: ₩7.84b (up 34% from 1Q 2024). Net income: ₩24.1m (up ₩1.66b from 1Q 2024). Profit margin: 0.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
분석 기사 • Apr 23Revenues Tell The Story For GL Pharm Tech Corp. (KOSDAQ:204840) As Its Stock Soars 45%The GL Pharm Tech Corp. ( KOSDAQ:204840 ) share price has done very well over the last month, posting an excellent gain...
New Risk • Apr 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩5.0b free cash flow). Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₩109.2b market cap, or US$76.8m).
Reported Earnings • Mar 22Full year 2024 earnings released: ₩31.00 loss per share (vs ₩60.00 loss in FY 2023)Full year 2024 results: ₩31.00 loss per share (improved from ₩60.00 loss in FY 2023). Revenue: ₩26.0b (flat on FY 2023). Net loss: ₩2.34b (loss narrowed 38% from FY 2023). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.
공시 • Mar 13GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2025GL Pharm Tech Corp., Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 257, saemaeul-ro, bundang-gu, gyeonggi-do, seongnam South Korea
New Risk • Aug 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩4.8b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩4.8b free cash flow). Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (₩80.8b market cap, or US$60.4m).
분석 기사 • Jul 23Is GL Pharm Tech (KOSDAQ:204840) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Apr 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩101.2b market cap, or US$73.6m).
New Risk • Mar 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩104.5b market cap, or US$77.7m).
Reported Earnings • Mar 21Full year 2023 earnings released: ₩60.00 loss per share (vs ₩13.00 loss in FY 2022)Full year 2023 results: ₩60.00 loss per share (further deteriorated from ₩13.00 loss in FY 2022). Revenue: ₩26.0b (up 56% from FY 2022). Net loss: ₩3.75b (loss widened 374% from FY 2022). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
공시 • Mar 07W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity FundW Science Co., Ltd. agreed to acquire a 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund for KRW 15.77 billion on September 14, 2023. W Science Co., Ltd. entered into an agreement to acquire 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund, KAIS Inc and Hoon-sik Wang for KRW 15.77 billion on February 28, 2024. The offer per share is KRW 1700 per share. The scheduled transaction closing date is April 29, 2024. W Science Co., Ltd. completed the acquisition of 14.75% stake in GL Pharm Tech Corp. (KOSDAQ:A204840) from Ideal Private Equity Fund on March 6, 2024.
공시 • Mar 06GL Pharm Tech Corp. announced that it has received KRW 9.199999458 billion in funding from W Science Co., Ltd.On March 6, 2024, GL Pharm Tech Corp. closed the transaction.
분석 기사 • Mar 01Market Participants Recognise GL Pharm Tech Corp.'s (KOSDAQ:204840) Revenues Pushing Shares 25% HigherGL Pharm Tech Corp. ( KOSDAQ:204840 ) shares have had a really impressive month, gaining 25% after a shaky period...
Reported Earnings • Nov 15Third quarter 2023 earnings released: ₩15.00 loss per share (vs ₩5.00 loss in 3Q 2022)Third quarter 2023 results: ₩15.00 loss per share (further deteriorated from ₩5.00 loss in 3Q 2022). Revenue: ₩7.69b (up 64% from 3Q 2022). Net loss: ₩963.6m (loss widened 280% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
New Risk • Nov 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩3.1b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩3.1b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (₩78.1b market cap, or US$59.9m).
New Risk • Jul 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩67.7b market cap, or US$52.6m).
Reported Earnings • May 14First quarter 2023 earnings released: ₩10.00 loss per share (vs ₩42.00 loss in 1Q 2022)First quarter 2023 results: ₩10.00 loss per share (improved from ₩42.00 loss in 1Q 2022). Revenue: ₩5.11b (up 103% from 1Q 2022). Net loss: ₩598.2m (loss narrowed 73% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 08Third quarter 2022 earnings released: ₩5.00 loss per share (vs ₩5.00 loss in 3Q 2021)Third quarter 2022 results: ₩5.00 loss per share (in line with 3Q 2021). Revenue: ₩4.70b (up 88% from 3Q 2021). Net loss: ₩306.2m (loss narrowed 78% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
분석 기사 • Mar 30Would GL Pharm Tech (KOSDAQ:204840) Be Better Off With Less Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
분석 기사 • Dec 15The GL Pharm Tech (KOSDAQ:204840) Share Price Is Up 50% And Shareholders Are Holding OnPassive investing in index funds can generate returns that roughly match the overall market. But one can do better than...
Is New 90 Day High Low • Dec 02New 90-day high: ₩1,190The company is up 17% from its price of ₩1,015 on 03 September 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
공시 • Nov 25GL Pharm Tech Corp. announced that it expects to receive KRW 4.5 billion in funding from Ideal Priavate Equity 1 Co., Ltd.GL Pharm Tech Corp. (KOSDAQ:A204840) announced a private placement of series 6 non-guaranteed private equity convertible bonds with registered interest for gross proceeds of KRW 4,500,000,000 on November 23, 2020. The transaction will include participation from Ideal Priavate Equity 1 Co., Ltd. The bonds will have interest rate of 4% and surface to interest rate 2% and will mature on November 29, 2025. The bonds to be issued are 100% convertible into 4,950,495 shares at a price of KRW 909 for 10.49% equity during the period November 30, 2021 to November 29, 2025. The subscription date is November 23, 2020 and payment date is November 30, 2020. The security to be issued in the transaction will be subject to hold period of one year. The transaction has been approved by the board of directors of the company.
Is New 90 Day High Low • Oct 30New 90-day low: ₩875The company is down 14% from its price of ₩1,020 on 31 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
공시 • Sep 30GL Pharm Tech Corp. announced that it has received KRW 1.000000232 billion in funding from Kyperion Co., Ltd.On September 29, 2020, GL Pharm Tech Corp. (KOSDAQ:A204840) closed the transaction.
Is New 90 Day High Low • Sep 24New 90-day low: ₩896The company is down 10.0% from its price of ₩992 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 23% over the same period.
공시 • Sep 22GL Pharm Tech Corp. announced that it expects to receive KRW 1.000000232 billion in funding from Kyperion Co., Ltd.GL Pharm Tech Corp. (KOSDAQ:A204840) announced a private placement of 1,152,074 common of par value KRW 100 per share, at an issue price of KRW 868 per share for gross proceeds of KRW 1,000,000,232 on September 21, 2020. The transaction will include participation from Kyperion Co., Ltd for all the shares in the transaction. The company will raise the funding through third party allocation method. The total number of shares issued before the transaction is 46,058,145 shares. All securities to be issued in the transaction will be subject to a lock-up period of one year. The transaction was approved by the bard of directors of the company, and is expected to close on September 29, 2020. The securities are issued at 10% per discount.